Radius Health PP&E per Employee
Delisted·Jul 10, 2025
PP&E per Employee of Radius Health (RDUS) as of Aug 12, 2026.
Get this data via API
Financial Data API
PP&E per Employee
0.00USD
Last updated:
PP&E per Employee of Radius Health is 2026 0.00 USD. PP&E per Employee of Radius Health was 2025 0.00 USD. It decreases by % lower compared to the previous year.
Access this data via the Eulerpool API
Radius Health Stock analysis
What does Radius Health do? Radius Health Inc. is an American pharmaceutical company specializing in the research, development, and marketing of products in the areas of osteoporosis, cancer therapy, and endocrinology. The company was founded in 2003 and is headquartered in Waltham, Massachusetts.
The history of Radius Health Inc. began with the discovery of a new compound called Abaloparatide, which was intended for use in the treatment of osteoporosis. The company initiated a Phase III clinical trial to evaluate the efficacy and tolerability of the medication. In 2016, Abaloparatide was approved by the U.S. Food and Drug Administration (FDA) for the treatment of postmenopausal osteoporosis.
Since then, Radius Health Inc. has evolved into a leading company specializing in improving women's health. The company has expanded its activities to include oncology and endocrinology and relies on innovative technologies and research to provide better treatment options and medications for patients.
The business model of Radius Health Inc. is based on the development and marketing of cost-effective and effective products for the treatment of diseases. The company conducts extensive clinical research and strives to develop new drugs and therapies to improve the lives of women. Radius Health Inc. employs an open and agile corporate culture that promotes innovation and prioritizes the needs of patients.
The products offered by Radius Health Inc. include a wide range of medications used in the treatment of osteoporosis, breast cancer, and other diseases. Abaloparatide, the company's flagship product, is a recombinant peptide agonist that stimulates bone formation and reduces the risk of fractures in postmenopausal women. Other products include Elacestrant, an investigative drug for the treatment of breast cancer, and RAD1901, a selective estrogen receptor modulator used in the treatment of hormone-dependent cancers.
The company is also active in the field of digital health. Radius Health Inc. has developed an augmented reality app that assists doctors and patients in visualizing bone fractures and other conditions. The app is currently being tested in clinical trials and is expected to be widely used in the future.
Overall, Radius Health Inc. is known for its innovative research activities and efforts to improve women's health. The company has an experienced and dedicated team of researchers, scientists, and executives working together to create better treatment options for patients. With a strong pipeline of products and a vision for the future of healthcare, Radius Health Inc. is on track to become a leading provider of medical products and services. Radius Health is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Radius Health stock
On Eulerpool you can find the complete historical development of PP&E per Employee Radius Health since 2006 – with annual values, charts, and detailed analysis.
PP&E per employee measures the physical capital intensity per worker. Higher values indicate more capital-intensive operations.
PP&E per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track PP&E per Employee's Radius Health historically and in real time.
Access this data via the Eulerpool API
Workforce — Radius Health
All Key Metrics — Radius Health
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth